Prediction of Clinical Response to Antidepressants in Patients with Depression: Neurophysiology in Clinical Practice

Clinical EEG and Neuroscience

Volumn 38, Issue 2, 2007, Pages 74-77

  Pogarell, Oliver ^a   Juckel, Georg ^b   Norra, Christine ^c   Leicht, Gregor ^a   Karch, Susanne ^a   Schaaff, Nadine ^a   Folkerts, Malte ^a   Ibrahim, Ahmad ^a   Mulert, Christoph ^a   Hegerl, Ulrich ^d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Antidepressants; Clinical Response Prediction; Evoked Potentials; Loudness Dependence; Noradrenergic System; Serotonergic System

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN MONOAMINE; CITALOPRAM; REBOXETINE; SEROTONIN UPTAKE INHIBITOR;

CLINICAL PRACTICE; CONFERENCE PAPER; COST OF ILLNESS; DEPRESSION; DISEASE DURATION; HUMAN; MONOAMINERGIC SYSTEM; NEUROPHYSIOLOGY; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; SEROTONINERGIC SYSTEM; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ACOUSTIC STIMULATION; ANTIDEPRESSIVE AGENTS; DEPRESSION; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; HUMANS; NEUROPHYSIOLOGY; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; TREATMENT OUTCOME;

EID: 34249880389     PISSN: 15500594     EISSN: None     Source Type: Journal    
DOI: 10.1177/155005940703800208     Document Type: Article

References (42)

1. Thase ME. Effectiveness of antidepressants: Comparative remission rates. J Clin Psychiatry 2003; 64 (suppl 2): 3-7.
2. Adli M Rush AJ Moller HJ Bauer M. Algorithms for optimizing the treatment of depression: Making the right decision at the right time. Pharmacopsychiatry 2003; 36 (suppl 3): S222-229.
3. Ressler KJ Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000; 12 (suppl 1): 2-19.
4. Joyce PR Paykel ES. Predictors of drug response in depression. Arch Gen Psychiatry 1989; 46(1): 89-99.
5. Yatham LN Steiner M. Neuroendocrine probes of serotonergic function: A critical review. Life Sci 1993; 53(6): 447-463.
6. Moore P Landolt HP Seifritz E Clark C Bhatti T Kelsoe J, et al. Clinical and physiological consequences of rapid tryptophan depletion. Neuropsychopharmacology 2000; 23(6): 601-622.
7. Hegerl U Juckel G. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: A new hypothesis. Biol Psychiatry 1993; 33(3): 173-187.
8. Hegerl U Juckel G. Auditory evoked dipole source activity: Indicator of central serotonergic dysfunction in psychiatric patients? Pharmacopsychiatry 1994; 27(2): 75-78.
9. Hegerl U Juckel G Schmidt LG Rommelspacher H. Serotonergic ethanol effects and auditory evoked dipole activity in alcoholic and healthy subjects. Psychiatry Res 1996; 63(1): 47-55.
10. Hegerl U Lipperheide K Juckel G Schmidt LG Rommelspacher H. Antisocial tendencies and cortical sensory-evoked responses in alcoholism. Alcohol Clin Exp Res 1995; 19(1): 31-36.
11. Azmitia EC Gannon PJ. The primate serotonergic system: A review of human and animal studies and a report on Macaca fascicularis. Adv Neurol 1986; 43: 407-468.
12. Lewis DA Campbell MJ Foote SL Morrison JH. The monoaminergic innervation of primate neocortex. Hum Neurobiol 1986; 5(3): 181-188.
13. Juckel G Hegerl U Molnar M Csepe V Karmos G. Auditory evoked potentials reflect serotonergic neuronal activity: A study in behaving cats administered drugs acting on 5-HT1A autoreceptors in the dorsal raphe nucleus. Neuropsychopharmacology 1999; 21(6): 710-716.
14. Scherg M Picton TW. Separation and identification of event-related potential components by brain electric source analysis. Electroencephalogr Clin Neurophysiol (suppl) 1991; 42: 24-37.
15. Hegerl U Gallinat J Mrowinski D. Intensity dependence of auditory evoked dipole source activity. Int J Psychophysiol 1994; 17(1): 1-13.
16. Tuchtenhagen F Daumann J Norra C Gobbele R Becker S Pelz S, et al. High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users. Neuropsychopharmacology 2000; 22(6): 608-617.
17. Norra C Mrazek M Tuchtenhagen F Gobbele R Buchner H Sass H, et al. Enhanced intensity dependence as a marker of low serotonergic neurotransmission in borderline personality disorder. J Psychiatr Res 2003; 37(1): 23-33.
18. Bruneau N Barthelemy C Roux S Jouve J Lelord G. Auditory evoked potential modifications according to clinical and biochemical responsiveness to fenfluramine treatment in children with autistic behavior. Neuropsychobiology 1989; 21(1): 48-52.
19. Gallinat J Bottlender R Juckel G Munke-Puchner A Stotz G Kuss HJ, et al. The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology (Berl) 2000; 148(4): 404-411.
20. Roon KL Sandor PS Schoonman GG Lamers FP Schoenen J Ferrari MD, et al. Auditory evoked potentials in the assessment of central nervous system effects of antimigraine drugs. Cephalalgia 1999; 19(10): 880-885.
21. Hegerl U Bottlender R Gallinat J Kuss HJ Ackenheil M Moller H.J., The serotonin syndrome scale: First results on validity. Eur Arch Psychiatry Clin Neurosci 1998; 248(2): 96-103.
22. Pogarell O Tatsch K Juckel G Hamann C Mulert C Popperl G, et al. Serotonin and dopamine transporter availabilities correlate with the loudness dependence of auditory evoked potentials in patients with obsessive-compulsive disorder. Neuropsychopharmacology 2004; 29(10): 1910-1917.
23. Gallinat J Senkowski D Wernicke C Juckel G Becker I Sander T, et al. Allelic variants of the functional promoter polymorphism of the human serotonin transporter gene is associated with auditory cortical stimulus processing. Neuropsychopharmacology 2003; 28(3): 530-532.
24. Strobel A Debener S Schmidt D Hunnerkopf R Lesch KP Brocke B. Allelic variation in serotonin transporter function associated with the intensity dependence of the auditory evoked potential. Am J Med Genet 2003; 118B(1): 41-47.
25. Hegerl U Gallinat J Mrowinski D. Sensory cortical processing and the biological basis of personality. Biol Psychiatry 1995; 37(7): 467-472.
26. Mulert C Juckel G Augustin H Hegerl U. Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective serotonin reuptake inhibitor citalopram in major depression. Clin Neurophysiol 2002; 113(10): 1566-1572.
27. Mulert C Jager L Propp S Karch S Stormann S Pogarell O, et al. Sound level dependence of the primary auditory cortex: Simultaneous measurement with 61-channel EEG and fMRI. Neuroimage 2005; 28(1): 49-58.
28. Dierks T Barta S Demisch L Schmeck K Englert E Kewitz A, et al. Intensity dependence of auditory evoked potentials (AEPs) as biological marker for cerebral serotonin levels: Effects of tryptophan depletion in healthy subjects. Psychopharmacology (Berl) 1999; 146(1): 101-107.
29. Debener S Strobel A Kurschner K Kranczioch C Hebenstreit J Maercker A, et al. Is auditory evoked potential augmenting/reducing affected by acute tryptophan depletion? Biol Psychol 2002; 59(2): 121-133.
30. Massey AE Marsh VR McAllister-Williams RH. Lack of effect of tryptophan depletion on the loudness dependency of auditory event related potentials in healthy volunteers. Biol Psychol 2004; 65(2): 137-145.
31. Uhl I Gorynia I Gallinat J Mulert C Wutzler A Heinz A, et al. Is the loudness dependence of auditory evoked potentials modulated by the selective serotonin reuptake inhibitor citalopram in healthy subjects? Hum Psychopharmacol 2006; 21(7): 463-471.
32. Kahkonen S Jaaskelainen IP Pennanen S Liesivuori J Ahveninen J. Acute tryptophan depletion decreases intensity dependence of auditory evoked magnetic N1/P2 dipole source activity. Psychopharmacology (Berl) 2002; 164(2): 221-227.
33. Nathan PJ Segrave R Phan KL O'Neill B Croft RJ. Direct evidence that acutely enhancing serotonin with the selective serotonin reuptake inhibitor citalopram modulates the loudness dependence of the auditory evoked potential (LDAEP) marker of central serotonin function. Hum Psychopharmacol 2006; 21(1): 47-52.
34. von Knorring L Perris C. Biochemistry of the augmenting-reducing response in visual evoked potentials. Neuropsychobiology 1981; 7(1): 1-8.
35. Bruneau N Barthelemy C Jouve J Lelord G. Frontal auditory-evoked potential augmenting-reducing and urinary homovanillic acid. Neuropsychobiology 1986; 16(2-3): 78-84.
36. Paige SR Fitzpatrick DF Kline JP Balogh SE Hendricks SE. Event-related potential amplitude/intensity slopes predict response to antidepressants. Neuropsychobiology 1994; 30(4): 197-201.
37. Linka T Muller BW Bender S Sartory G. The intensity dependence of the auditory evoked N1 component as a predictor of response to Citalopram treatment in patients with major depression. Neurosci Lett 2004; 367(3): 375-378.
38. Hegerl U Wulff H Muller-Oerlinghausen B. Intensity dependence of auditory evoked potentials and clinical response to prophylactic lithium medication: A replication study. Psychiatry Res 1992; 44(3): 181-190.
39. Hegerl U Ulrich G Muller-Oerlinghausen B. Auditory evoked potentials and response to lithium prophylaxis. Pharmacopsychiatry 1987; 20(5): 213-216.
40. Hegerl U Wulff H Muller-Oerlinghausen B. Intensity dependence of auditory evoked potentials and clinical response to prophylactic lithium medication: A replication study. Psychiatry Res 1992; 44(3): 181-190.
41. Linka T Muller BW Bender S Sartory G Gastpar M. The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression. Pharmacopsychiatry 2005; 38(3): 139-143.
42. Juckel G Pogarell O Augustin H Mulert C Müller-Siecheneder F Frodl T, et al. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depression. J Clin Psychiatry 2007, In press.